Xiaoying Quan. A case of sorafenib-induced severe thrombocytopenia during treatment of unresectable hepatocellular carcinoma. Oncol Transl Med, 2021, 7: 235-238. |
A case of sorafenib-induced severe thrombocytopenia during treatment of unresectable hepatocellular carcinoma |
Received:April 18, 2021 Revised:October 22, 2021 |
View Full Text View/Add Comment Download reader |
KeyWord:thrombocytopenia; sorafenib; hepatocellular carcinoma |
Author Name | Affiliation | E-mail | Xiaoying Quan | The Sixth People''s Hospital of Chengdu | 1193084163@qq.com |
|
Hits: 3642 |
Download times: 3835 |
Abstract: |
An 81-year-old male with unresectable hepatocellular carcinoma underwent transarterial chemoembolization
(TACE) combined with sorafenib. Platelet count was normal before and after TACE treatment, after which
oral administration of sorafenib (400 mg po bid) was initiated. During this period, the patient experienced
significant diarrhea, so the dosage was reduced to 200 mg po bid. Later, the patient showed obvious
gingival bleeding with progressive exacerbation, and his blood routine examination showed a platelet count
of 2 × 109 cells/L. The patient was clinically diagnosed with extreme severe thrombocytopenia. The patient
was advised to stop taking sorafenib and was immediately treated with hemostasis, platelet transfusion,
and suspended red blood cells. After the above treatment, the patient’s symptoms improved, and he was
discharged. Up to the date of follow-up, there was no further bleeding. |
Close |
|
|
|